Unknown

Dataset Information

0

Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.


ABSTRACT:

Purpose of review

We provide an updated review of clinical trials evaluating the combination of BRAF/MEK inhibitors with anti-PD-(L)1 therapy (triplet therapy) for patients with advanced BRAF-mutant melanoma, accompanied by a summary of the biological evidence supporting this combination.

Recent findings

Resistance to BRAF/MEK inhibition and comparatively low response rates to immune checkpoint inhibitors remain clinical challenges in the treatment of melanoma. Preclinical data demonstrates that targeted therapy is immune-modulatory and synergises with immune checkpoint inhibition. Several randomised controlled trials have evaluated the combination of targeted therapy with immune checkpoint inhibition. Triplet therapy has shown improvements in progression-free survival and durability of response compared to BRAF/MEK inhibition alone; however, questions remain regarding the best clinical scenario for implementation of this regimen in the era of front-line immunotherapy.

SUBMITTER: Dixon-Douglas JR 

PROVIDER: S-EPMC9249697 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8562134 | biostudies-literature
| S-EPMC7352575 | biostudies-literature
| S-EPMC8007796 | biostudies-literature
| S-EPMC3549295 | biostudies-literature
| S-EPMC4699264 | biostudies-literature
| S-EPMC6029356 | biostudies-literature
| S-EPMC8616282 | biostudies-literature
2014-12-12 | E-GEOD-64102 | biostudies-arrayexpress
| S-EPMC4765379 | biostudies-literature
| S-EPMC8469254 | biostudies-literature